NasdaqGM:MRNS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Marinus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRNS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-27.3%

MRNS

2.1%

US Pharmaceuticals

1.5%

US Market


1 Year Return

-54.7%

MRNS

9.0%

US Pharmaceuticals

8.7%

US Market

Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 7.2% over the past year.

Return vs Market: MRNS underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

MRNSIndustryMarket
7 Day-27.3%2.1%1.5%
30 Day-27.0%7.5%5.8%
90 Day2.8%2.3%18.4%
1 Year-54.7%-54.7%11.9%9.0%11.1%8.7%
3 Year10.8%10.8%26.3%17.1%36.9%28.0%
5 Year-88.4%-88.4%28.4%13.9%66.8%48.7%

Price Volatility Vs. Market

How volatile is Marinus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Marinus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MRNS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MRNS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MRNS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: MRNS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRNS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRNS is overvalued based on its PB Ratio (3.7x) compared to the US Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Marinus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

42.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRNS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRNS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MRNS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MRNS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MRNS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Marinus Pharmaceuticals performed over the past 5 years?

-22.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRNS is currently unprofitable.

Growing Profit Margin: MRNS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MRNS is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.

Accelerating Growth: Unable to compare MRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRNS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).


Return on Equity

High ROE: MRNS has a negative Return on Equity (-84.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is Marinus Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: MRNS's short term assets ($80.0M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: MRNS's short term assets ($80.0M) exceed its long term liabilities ($2.9M).


Debt to Equity History and Analysis

Debt Level: MRNS is debt free.

Reducing Debt: MRNS has no debt compared to 5 years ago when its debt to equity ratio was 20.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MRNS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MRNS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 23.9% each year.


Next Steps

Dividend

What is Marinus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRNS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Scott Braunstein (57yo)

0.92

Tenure

US$2,245,684

Compensation

Dr. Scott Braunstein, M.D., serves as Director at Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, Inc.). since June 2018. He served as Chairman of the Board at ArTara Therapeutics, Inc)  ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD2.25M) is above average for companies of similar size in the US market ($USD1.34M).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Director0.92yrUS$2.25m0.082% $184.0k
Edward Smith
VP, CFO6.67yrsUS$1.25m0.015% $32.6k
Joseph Hulihan
Chief Medical Officer0.75yrUS$734.30kno data
Lisa Caperelli
Executive Director of Investor & Strategic Relationsno datano datano data
Martha Manning
VP, General Counsel & Secretary0.083yrno datano data
Sasha Damouni Ellis
Vice President of Investor Relations & Corporate Communication0.33yrno datano data
Thomas Lyons
Vice President of Corporateno datano datano data
Kimberly McCormick
Vice President Regulatory Affairsno datano datano data
Alex Aimetti
Head of Scientific Affairsno datano datano data

0.8yrs

Average Tenure

60.5yo

Average Age

Experienced Management: MRNS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Director0.92yrUS$2.25m0.082% $184.0k
Nicole Vitullo
Independent Chairman of the Board0.92yrUS$174.94k0.041% $92.6k
Michael Dougherty
Independent Director3.42yrsUS$162.70k0.0074% $16.6k
Timothy Mayleben
Independent Director11.58yrsUS$180.47k0.041% $92.6k
Elan Ezickson
Independent Director0.58yrUS$154.32kno data
Seth H. Fischer
Independent Director3.83yrsUS$161.20k0.0091% $20.4k
Enrique Carrazana
Independent Director6.67yrsUS$158.96k0.026% $58.5k

3.4yrs

Average Tenure

59yo

Average Age

Experienced Board: MRNS's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 132.5%.


Top Shareholders

Company Information

Marinus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Marinus Pharmaceuticals, Inc.
  • Ticker: MRNS
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$224.838m
  • Shares outstanding: 122.19m
  • Website: https://www.marinuspharma.com

Number of Employees


Location

  • Marinus Pharmaceuticals, Inc.
  • 5 Radnor Corporate Center
  • Suite 500
  • Radnor
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2014
0MVDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2014
MRNS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNAug 2014
0JYLLSE (London Stock Exchange)YesCommon StockGBUSDAug 2014

Biography

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/15 23:59
End of Day Share Price2020/07/15 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.